129 results on '"Somervaille, Tim C.P."'
Search Results
2. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
3. Differentiation block in acute myeloid leukemia regulated by intronic sequences of FTO
4. A stress-responsive enhancer induces dynamic drug resistance in acute myeloid leukemia
5. MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
6. POSTER: MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
7. Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
8. Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib
9. Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia
10. A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
11. The Functional and Molecular Alterations in Human Bone Marrow Mesenchymal Stem Cells in Chronic Myelomonocytic Leukemia
12. Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
13. Integrative Analysis of Blast Phase Chronic Myelomonocytic Leukemia Reveals Distinct Transformation Phenotypes Predictive of Drug Response
14. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
15. The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
16. Iadademstat in Combination with Azacitidine Generates Robust and Long Lasting Responses in AML Patients (ALICE Trial)
17. Multi-Omic Analysis of Chronic Myelomonocytic Leukaemia Monocytes Reveals Immune Dysregulation Mediated By TGF-β Activation
18. Multiomic Single-Cell Sequencing Reveals Patterns of Disease Evolution and Acute Transformation in Chronic Myelomonocytic Leukaemia
19. CCS1477, a Novel p300/CBP Bromodomain Inhibitor, Enhances Efficacy of Azacitidine and Venetoclax in Pre-Clinical Models of Acute Myeloid Leukaemia and Lymphoma
20. Chronic myeloid leukemia presenting as compartment syndrome with acute loss of upper limb function
21. Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
22. Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia
23. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy
24. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1 ‐ JAK2 , BCR‐JAK2 and ETV6‐ABL1 fusion genes
25. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia
26. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
27. Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]
28. Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)
29. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia
30. Response to tyrosine kinase inhibitors in myeloid neoplasms associated withPCM1 ‐ JAK2,BCR‐JAK2andETV6‐ABL1fusion genes
31. Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1
32. Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia
33. AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells
34. Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1
35. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax
36. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes.
37. Revert the SIRT: Normalizing SIRT1 Activity in Myelodysplastic Stem Cells
38. LSD1 inhibitors disrupt the GFI1 transcription repressor complex
39. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
40. Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia
41. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell protein
42. PU.1 and Junb: Suppressing the formation of acute myeloid leukemia stem cells
43. Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage
44. Leukemogenic Activity of Cohesin Rings True
45. Frequent Derepression of the Mesenchymal Transcription Factor Gene FOXC1 in Acute Myeloid Leukemia
46. Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3Confers Differentiation Block in Acute Leukemia
47. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1
48. The miR-17-92 microRNA Polycistron Regulates MLL Leukemia Stem Cell Potential by Modulating p21 Expression
49. Mutant CEBPA: Priming Stem Cells for Myeloid Leukemogenesis
50. Hierarchical Maintenance of MLL Myeloid Leukemia Stem Cells Employs a Transcriptional Program Shared with Embryonic Rather Than Adult Stem Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.